Education
About Us
Working with TipRanks
Follow Us
Modus Therapeutics Holding AB (DE:99Z)
FRANKFURT:99Z
Total Valuation
Modus Therapeutics Holding AB has a market cap or net worth of €4.89M. The enterprise value is €49.35M.
Market Cap€4.89M
Enterprise Value€49.35M
Share Statistics
Modus Therapeutics Holding AB has 35,938,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding35,938,900
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Modus Therapeutics Holding AB’s return on equity (ROE) is -7.27 and return on invested capital (ROIC) is -741.13%.
Return on Equity (ROE)-7.27
Return on Assets (ROA)-3.18
Return on Invested Capital (ROIC)-741.13%
Return on Capital Employed (ROCE)-7.41
Revenue Per Employee0.00
Profits Per Employee-7.77M
Employee Count2
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Modus Therapeutics Holding AB is -4.18. Modus Therapeutics Holding AB’s PEG ratio is -0.33.
PE Ratio-4.18
PS Ratio0.00
PB Ratio25.14
Price to Fair Value30.44
Price to FCF-3.66
Price to Operating Cash Flow-3.66
PEG Ratio-0.33
Income Statement
In the last 12 months, Modus Therapeutics Holding AB had revenue of 0.00 and earned -15.54M in profits. Earnings per share was -0.43.
Revenue0.00
Gross Profit0.00
Operating Income-15.84M
Pretax Income-15.54M
Net Income-15.54M
EBITDA-15.84M
Earnings Per Share (EPS)-0.43
Cash Flow
In the last 12 months, operating cash flow was -14.68M and capital expenditures 0.00, giving a free cash flow of -14.68M billion.
Operating Cash Flow-14.68M
Free Cash Flow-14.68M
Free Cash Flow per Share-0.41
Dividends & Yields
Modus Therapeutics Holding AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.61
52-Week Price Change33.33%
50-Day Moving Average0.11
200-Day Moving Average0.12
Relative Strength Index (RSI)53.35
Average Volume (3m)0.00
Important Dates
Modus Therapeutics Holding AB upcoming earnings date is Aug 27, 2025, TBA Not Confirmed.
Last Earnings DateMay 14, 2025
Next Earnings DateAug 27, 2025
Ex-Dividend Date―
Financial Position
Modus Therapeutics Holding AB as a current ratio of 1.76, with Debt / Equity ratio of 0.00%
Current Ratio1.76
Quick Ratio1.76
Debt to Market Cap0.00
Net Debt to EBITDA0.28
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Modus Therapeutics Holding AB has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Modus Therapeutics Holding AB EV to EBITDA ratio is -3.83, with an EV/FCF ratio of -4.13.
EV to Sales0.00
EV to EBITDA-3.83
EV to Free Cash Flow-4.13
EV to Operating Cash Flow-4.13
Balance Sheet
Modus Therapeutics Holding AB has €4.38M in cash and marketable securities with kr0.00 in debt, giving a net cash position of -€4.38M billion.
Cash & Marketable Securities€4.38M
Total Debtkr0.00
Net Cash-€4.38M
Net Cash Per Share-€0.12
Tangible Book Value Per Share€0.06
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Modus Therapeutics Holding AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―